[go: up one dir, main page]

WO2017046226A3 - Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique et ses utilisations - Google Patents

Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique et ses utilisations Download PDF

Info

Publication number
WO2017046226A3
WO2017046226A3 PCT/EP2016/071792 EP2016071792W WO2017046226A3 WO 2017046226 A3 WO2017046226 A3 WO 2017046226A3 EP 2016071792 W EP2016071792 W EP 2016071792W WO 2017046226 A3 WO2017046226 A3 WO 2017046226A3
Authority
WO
WIPO (PCT)
Prior art keywords
neoplastic cell
association
growth factor
factor receptor
cyclin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/071792
Other languages
English (en)
Other versions
WO2017046226A2 (fr
Inventor
Omar F. ZOUANI
Veronika GOCHEVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Histide AG
Original Assignee
Histide AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Histide AG filed Critical Histide AG
Publication of WO2017046226A2 publication Critical patent/WO2017046226A2/fr
Publication of WO2017046226A3 publication Critical patent/WO2017046226A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une association pharmaceutique à utiliser dans le traitement, la prévention et/ou le diagnostic d'une maladie néoplasique, ladite association comprenant au moins un composé de liaison au récepteur du facteur de croissance, qui active au moins un récepteur du facteur de croissance d'une cellule néoplasique, et au moins un support bioactif formant au moins une interaction covalente ou non-covalente avec ledit ou lesdits composés de liaison au récepteur du facteur de croissance, ladite association réduisant ou supprimant, dans la cellule néoplasique, l'expression génique d'une ou de plusieurs cyclines D et/ou réduisant ou supprimant la formation d'un ou de plusieurs complexes formés entre ladite ou lesdites cyclines D d'une part et la kinase dépendant de la cycline 4 et/ou la kinase dépendant de la cycline 6 d'autre part.
PCT/EP2016/071792 2015-09-17 2016-09-15 Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique et ses utilisations Ceased WO2017046226A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219725P 2015-09-17 2015-09-17
US62/219,725 2015-09-17

Publications (2)

Publication Number Publication Date
WO2017046226A2 WO2017046226A2 (fr) 2017-03-23
WO2017046226A3 true WO2017046226A3 (fr) 2017-06-29

Family

ID=56985597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/071792 Ceased WO2017046226A2 (fr) 2015-09-17 2016-09-15 Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique et ses utilisations

Country Status (1)

Country Link
WO (1) WO2017046226A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11299513B2 (en) 2017-07-28 2022-04-12 Circle Pharma, Inc. Cyclative release of peptidic compounds
CN114262372B (zh) * 2021-12-24 2023-07-14 同济大学 一种调控细胞成骨分化的转录因子及成骨分化细胞

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
WO2005030933A2 (fr) * 2003-09-24 2005-04-07 Genera Doo Proteine morphogenetique osseuse 7 (bmp-7) utilisee dans le diagnostic et le traitement du cancer
WO2007010394A2 (fr) * 2005-07-19 2007-01-25 Stemgen S.P.A. Inhibition du potentiel tumorigene de cellules souches tumorales par lif (facteur inhibiteur de la leucemie) et bmps (proteines morphogenetiques osseuses)
WO2008150119A1 (fr) * 2007-06-05 2008-12-11 Seoul National University Industry Foundation Gel de régénération osseuse injectable contenant un peptide améliorant la formation osseuse
US7528105B1 (en) * 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
WO2014182676A2 (fr) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions et procédés de modulation du facteur de croissance

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
WO2005030933A2 (fr) * 2003-09-24 2005-04-07 Genera Doo Proteine morphogenetique osseuse 7 (bmp-7) utilisee dans le diagnostic et le traitement du cancer
US7528105B1 (en) * 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
WO2007010394A2 (fr) * 2005-07-19 2007-01-25 Stemgen S.P.A. Inhibition du potentiel tumorigene de cellules souches tumorales par lif (facteur inhibiteur de la leucemie) et bmps (proteines morphogenetiques osseuses)
WO2008150119A1 (fr) * 2007-06-05 2008-12-11 Seoul National University Industry Foundation Gel de régénération osseuse injectable contenant un peptide améliorant la formation osseuse
WO2014182676A2 (fr) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions et procédés de modulation du facteur de croissance

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GEIGER M ET AL: "Collagen sponges for bone regeneration with rhBMP-2", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 55, no. 12, 28 November 2003 (2003-11-28), pages 1613 - 1629, XP002764796, ISSN: 0169-409X *
IDE HISAMITSU ET AL: "Growth regulation of human prostate cancer cells by bone morphogenetic protein-2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 57, no. 22, 15 November 1997 (1997-11-15), pages 5022 - 5027, XP002441978, ISSN: 0008-5472 *
LIAO ANYAN ET AL: "Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer", TUMOR BIOLOGY, KARGER, BASEL, CH, vol. 36, no. 4, 3 December 2014 (2014-12-03), pages 2773 - 2778, XP036092591, ISSN: 1010-4283, [retrieved on 20141203], DOI: 10.1007/S13277-014-2901-1 *
SENTA H ET AL: "Cell responses to bone morphogenetic proteins and peptides derived from them: Biomedical applications and limitations", CYTOKINE AND GROWTH FACTOR REVIEWS, ELSEVIER LTD, GB, vol. 20, no. 3, 1 June 2009 (2009-06-01), pages 213 - 222, XP026210728, ISSN: 1359-6101, [retrieved on 20090602], DOI: 10.1016/J.CYTOGFR.2009.05.006 *
W. J. PETTY ET AL: "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Represses Cyclin D1 in Aerodigestive Tract Cancers", CLINICAL CANCER RESEARCH, vol. 10, no. 22, 15 November 2004 (2004-11-15), pages 7547 - 7554, XP055188457, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-04-1169 *

Also Published As

Publication number Publication date
WO2017046226A2 (fr) 2017-03-23

Similar Documents

Publication Publication Date Title
WO2017046215A3 (fr) Association pharmaceutique pour convertir une cellule néoplasique en cellule non-néoplasique et ses utilisations
USD843592S1 (en) Ejaculation promotion apparatus
USD786081S1 (en) Bottle for cosmetic products
USD757496S1 (en) Thermomug
USD812759S1 (en) Optical coherence tomography apparatus for ophthalmology
USD777325S1 (en) Syringe tip
USD796961S1 (en) Bottle with cap
USD806481S1 (en) Combined dish and cup
WO2017030823A3 (fr) Anticorps anti-tigit
WO2016037157A3 (fr) Ciblage de l'activité capn9/capns2 en tant que stratégie thérapeutique pour le traitement de la différentiation des myofibroblastes et des pathologies associées
WO2015134808A3 (fr) Préparations probiotiques et méthodes d'utilisation associées
USD790688S1 (en) Syringe
WO2016004213A3 (fr) Hydrogels pour traiter et améliorer des cancers et potentialiser le système immunitaire et procédés pour les produire et les utiliser
USD814307S1 (en) Perfume bottle
USD777898S1 (en) Pear shaped potpourri cage
USD800897S1 (en) Medicine injector
USD770096S1 (en) Mascara container
WO2016011049A3 (fr) Compositions et procédés pour le traitement de maladies à l'aide de composés distribués sous forme de nanoparticules
WO2015104658A3 (fr) Dispersion solide amorphe de dapagliflozine et procédé pour la préparation de dapagliflozine amorphe
USD852047S1 (en) Bottle
USD800568S1 (en) Aerosol container
WO2015159155A3 (fr) Nouvelles formulations d'adémétionine
WO2019092618A3 (fr) Oligonucléotides conjugués à une fraction ligand du récepteur de glp-1 et leurs utilisations
USD860799S1 (en) Perfume bottle
NZ629255A (en) A novel drug delivery system based on jcv-vlp

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16770238

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16770238

Country of ref document: EP

Kind code of ref document: A2